Aegerion Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2005-01-01
- Employees
- 236
- Market Cap
- -
- Website
- http://www.aegerion.com
Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04026178
- Locations
- 🇺🇸
Endocrinology Research Associates, Columbus, Ohio, United States
🇺🇸Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Registration Number
- NCT02765841
Effects of Lomitapide on Carotid and Aortic Atherosclerosis
Withdrawn
- Conditions
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Registration Number
- NCT02399852
MEASuRE: Metreleptin Effectiveness And Safety Registry
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02325674
- Locations
- 🇫🇷
Hôpital Robert Debré, Paris, Paris, France, France
🇺🇸University Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope, Duarte, California, United States
Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02173158
Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02080468
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Dallas, Texas, United States
Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02080455
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Dallas, Texas, United States
A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02044419
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, Croydon, Surrey, United Kingdom
Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01915771
- Locations
- 🇬🇧
Richmond Pharmacology, Croydon, Surrey, United Kingdom
Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT01760187
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, Croydon, Surrey, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath